US EditionJ&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
Johnson & Johnson will acquire Halda Therapeutics to enhance its oncology pipeline with a $3.05 billion cash deal for a clinical-stage biotech with a novel RIPTAC platform.
- Johnson & Johnson agreed to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash on Monday, acquiring the clinical-stage biotechnology company with its proprietary RIPTAC platform.
- Positioning Halda's platform as a strategic asset, Johnson & Johnson said the acquisition strengthens its deep oncology pipeline and offers a potential mid- and long-term growth catalyst beyond oncology.
- Halda's lead candidate HLD-0915 is a clinical-stage therapy for prostate cancer with 1.7 million projected new diagnoses globally by 2030 and shows preliminary efficacy and a strong early safety profile.
- J&J signaled a near-term financial impact, noting the deal will be accounted for as a business combination and is expected to close within the next few months, subject to antitrust clearance and customary closing conditions, with an expected $0.15 dilution in 2026 of Adjusted Earnings Per Share due to financing and equity awards for Halda employees.
- Johnson & Johnson warned that risks include regulatory approvals, integration challenges, and other uncertainties that could delay the transaction or expected benefits, and will discuss full year 2026 guidance on January 21, 2026.
20 Articles
20 Articles
Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion
Johnson & Johnson has had the year 2025 circled, highlighted, bolded and underlined on its calendar for a long time. Why? Because patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease, expired this year, allowing so-called “biosimilars” to hit the market. In turn, the company has embraced acquisitions to keep its pipeline flowing. On Monday, it announced an agreement to pay $3.1 billi…
J&J’s $3B Halda Acquisition Brings a Way to Overcome Drug Resistance in Prostate Cancer & More
Johnson & Johnson is acquiring Halda Therapeutics for its lead program, a drug that recently posted encouraging Phase 1 data in advanced prostate cancer. This drug comes from a proprietary Halda platform technology that yields oral small molecules offering a novel mechanism for killing cancer cells. The post J&J’s $3B Halda Acquisition Brings a Way to Overcome Drug Resistance in Prostate Cancer & More appeared first on MedCity News.
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
